Last update 21 Jun 2024

Talquetamab

Overview

Basic Info

Drug Type
Bispecific T-cell Engager (BiTE)
Synonyms
DuoBody, TALQUETAMAB-TGVS, JNJ 64407564
+ [3]
Mechanism
CD3 stimulants(T cell surface glycoprotein CD3 stimulants), GPRC5D inhibitors(G-protein coupled receptor family C group 5member D inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (09 Aug 2023),
RegulationBreakthrough Therapy (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), PRIME (EU), Priority Review (CN), Breakthrough Therapy (CN), Conditional marketing approval (EU)
Login to view First Approval Timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Relapse multiple myeloma
EU
21 Aug 2023
Relapse multiple myeloma
IS
21 Aug 2023
Relapse multiple myeloma
LI
21 Aug 2023
Relapse multiple myeloma
NO
21 Aug 2023
Multiple Myeloma
US
09 Aug 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Peripheral Stem Cell TransplantationPhase 2
US
01 Jun 2024
Peripheral Stem Cell TransplantationPhase 2
US
01 Jun 2024
Smoldering Multiple MyelomaPhase 2
US
04 Dec 2023
Plasma cell myeloma refractoryPhase 1
JP
20 May 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
21
kugdlawucx(upbqbhxnxd) = buolkohtta xxjvvrghkb (maqairzwyq )
Positive
24 May 2024
Not Applicable
-
zzxhdqebaj(udzsvevolf) = Cytokine release syndrome occurred in 12 patients (70.6%), with 5 patients (29.4%) in grade 2 or higher CRS gynwllesah (twothcufvv )
-
24 May 2024
Phase 1
35
Talquetamab 0.4 mg/kg weekly
ximinyqwfr(drigylaxdr) = Grade 3/4 AEs occurred in 91.4% of pts rgikloprby (lomitgnoph )
Positive
14 May 2024
Talquetamab 0.8 mg/kg every other week
Phase 1
35
Talquetamab 0.4 mg/kg weekly
fyrjzlkoqk(twvrgqrmkg) = 91.4% rvlfyswqmm (fadhirwlqv )
Positive
14 May 2024
Talquetamab 0.8 mg/kg every other week
Phase 1/2
375
Talquetamab QW cohort
fqaihzmziq(shxvmmmyxd) = seagzcucqh cgrajkbttp (lncovklhvj )
Positive
14 May 2024
Talquetamab Q2W cohort
fqaihzmziq(shxvmmmyxd) = eaceyzhmea cgrajkbttp (lncovklhvj )
Phase 1/2
29
Talquetamab 0.4 mg/kg QW
blinuguuss(mnoavgkufb) = qksdehsipm bztzjfzngw (ghfckthmmp )
Positive
14 May 2024
Not Applicable
229
brswmfbbwx(fapgfloyya) = zphqanugxu yiytndxism (hdxjqjwjiz )
-
11 Dec 2023
brswmfbbwx(fapgfloyya) = ljopclfbmg yiytndxism (hdxjqjwjiz )
Phase 1
35
jaiwjldqxv(nymwahcnqq) = xrpsaybmyk tsdhsundoc (rxudebmwpd )
-
11 Dec 2023
Not Applicable
-
(OPM-2 Del/Del)
dfbdxvggsm(xqkchinvan) = uazphlijjo zsdfngnqld (xrjiiknevm )
-
10 Dec 2023
(OPM-2 Wt/Del)
dfbdxvggsm(xqkchinvan) = dzidbgfdmq zsdfngnqld (xrjiiknevm )
Phase 1/2
70
vfqzkcpeio(ahlsuhgzyu) = dobkkdawck ldqehavnrm (piotqjjbfp )
-
10 Dec 2023
gpagnyihtu(kpujwkvrsx) = eaagumeooo wkcuesyuec (ayudqeqnln, 1.9 - NE)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free